Year All20242023202220212020 Apr 02, 2024 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes Read More Apr 01, 2024 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More Apr 01, 2024 Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs Read More Mar 12, 2024 Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity Read More Feb 20, 2024 Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials Read More Feb 01, 2024 Fractyl Health Announces Pricing of Initial Public Offering Read More Jan 05, 2024 Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in it's Rejuva® GLP-1 Gene Therapy Platform Read More
Apr 02, 2024 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
Apr 01, 2024 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Apr 01, 2024 Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Mar 12, 2024 Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
Feb 20, 2024 Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Jan 05, 2024 Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in it's Rejuva® GLP-1 Gene Therapy Platform